Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune & Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ERAP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ERAP1 Recombinant Protein (WT & Catalytic Mutant). High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified, Metal-ion Stabilized. Theoretical MW confirmed. | View ERAP1 Products |
| Gene Delivery | ERAP1 Premade Lentivirus / Promise-ORF. Full-length ORF for stable cell line construction (antigen presentation assays). | View ERAP1 Products |
| Benchmark Ab | Anti-ERAP1 (Clone OR-3E7 Equivalent / Research Grade). Recombinant detection antibody, Sequence Verified. Suitable for Western, IP, ELISA. | View ERAP1 Products |
| Validator | ERAP1 siRNA Set. For knockdown verification and specificity controls. | View ERAP1 Products |
| Related Target A | ERAP2. Homologous aminopeptidase for selectivity screening and counter-assays. | View ERAP2 Products |
| Related Target B | LNPEP (Leucyl/Cystinyl Aminopeptidase). M1 family member for subfamily off-target profiling. | View LNPEP Products |
| Related Target C | TAP1. Upstream transporter in antigen processing and presentation pathway. | View TAP1 Products |
Critical Assay Challenges
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homolog/Subfamily Selectivity (ERAP1 vs ERAP2 vs LNPEP vs IRAP) | Purified paralog panel (ERAP1, ERAP2, LNPEP, IRAP) available with >95% purity, mass spec verified, for side-by-side kinetic comparison. |
| Species Translation (Human/Mouse/Cyno) | Human/Mouse/Cyno ortholog proteins available with Theoretical MW confirmed, Endotoxin Controlled (<1 EU/µg). |
| Enzymatic Activity Standardization | Zinc-cofactor optimized formulation, High Purity (>95%) enabling consistent specific activity calibration. |
| Structural Biology & Co-crystallization | Catalytic mutant (E354A) and WT proteins available; endotoxin controlled; suitable for X-ray and cryo-EM. |
| False Positives & Lack of Controls in Screening | Validated siRNA included for target specificity confirmation; research-grade antibody for target engagement verification. |
Live ERAP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ERAP1 therapeutics is intensifying, transitioning from genetic association studies (ankylosing spondylitis GWAS, Behçet's disease) to druggable small-molecule programs. Major players are advancing first-generation active-site inhibitors into Phase I/II clinical trials. As these candidates proceed, the next wave of R&D is targeting selective ERAP1 modulators over ERAP2 and exploring allosteric sites for improved safety profiles. In parallel, combination regimens with checkpoint inhibitors are being pursued to reshape the immunopeptidome in solid tumors, converting cold tumors to hot. Emerging modalities like PROTAC degraders aim to address protein half-life and functional redundancy. This evolving landscape demands high-quality reagents for enzymatic, selectivity, and cell-based assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Priovant/J&J, Neurizon; early-stage biotech consortia; academic spin-outs | Ankylosing Spondylitis, Psoriasis, Behçet's Disease, Uveitis | Enzymatic Activity & Selectivity Panel (Need high-purity active ERAP1 protein with metal cofactor, WT + mutant, counter-screens for ERAP2/IRAP) |
| Allosteric Modulator | Academic Consortia | Autoimmune | Conformational Selectivity Assay (Need mutant variants and ortholog proteins) |
| PROTAC / Degrader | Targeted protein degradation platforms | Refractory Autoimmune Indications | Cell-line Construction (Need Lentivirus for stable ERAP1-FLAG expression) |
| Cancer Immunotherapy Modulator (Immunomodulatory Combo) | Early Biotech; Oncology immunotherapy developers | Solid Tumors (cold-to-hot) | Cell-based MHC Loading Assay / Immunopeptidome Validation (Need Lentivirus for stable overexpression lines, siRNA for specificity) |
关联靶点推荐 (Cross-sell Strategy)
基于抗原加工呈递(Ag Presentation)通路及M1氨基肽酶家族，推荐以下关联靶点用于完整药物发现方案：
- ERAP2: 与ERAP1形成功能冗余复合物，是选择性筛选的必需对照靶点。
- LNPEP: 溶酶体氨基肽酶，用于评估M1家族-wide的脱靶风险。
- TAP1/TAP2: 抗原加工相关转运蛋白，位于ERAP1上游，适用于通路完整研究及联合靶点筛选。
- IRAP (LNPEP): 与ERAP1/ERAP2同属M1家族，用于更全面的亚家族选择性筛选。